KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Income from Continuing Operations: 2020-2025

Historic Income from Continuing Operations for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$162.3 million.

  • Recursion Pharmaceuticals' Income from Continuing Operations fell 69.29% to -$162.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$715.5 million, marking a year-over-year decrease of 89.42%. This contributed to the annual value of -$463.7 million for FY2024, which is 41.33% down from last year.
  • Recursion Pharmaceuticals' Income from Continuing Operations amounted to -$162.3 million in Q3 2025, which was up 5.61% from -$171.9 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Income from Continuing Operations ranged from a high of -$30.5 million in Q1 2021 and a low of -$202.5 million during Q1 2025.
  • Over the past 3 years, Recursion Pharmaceuticals' median Income from Continuing Operations value was -$95.8 million (recorded in 2024), while the average stood at -$120.8 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 153.94% in 2021, then rose by 6.12% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then crashed by 52.50% to -$93.0 million in 2023, then plummeted by 92.38% to -$178.9 million in 2024, then plummeted by 69.29% to -$162.3 million in 2025.
  • Its Income from Continuing Operations was -$162.3 million in Q3 2025, compared to -$171.9 million in Q2 2025 and -$202.5 million in Q1 2025.